Overview
Haystack is an agent-native control layer for code changes [1] founded in 2024 [5] and headquartered in New York City [4]. The company is backed by Y Combinator, having been accepted to the Summer 2024 batch [3]. Haystack helps engineering teams manage the growing volume of AI-generated pull requests [2]. The platform integrates with GitHub and evaluates pull requests by examining the codebase, diff, agent trace, author intent, and verification evidence such as tests, logs, commands, or screenshots [2]. Based on this analysis, Haystack determines whether a change can proceed, requires fixes, or needs human review [2]. The company operates with a team of two [6].
Haystack helps engineering teams manage the growing volume of AI-generated pull requests. Coding agents make it much easier to produce code, but they also create a new problem: teams now have more changes to review, many of them larger, more frequent, and harder to trust at a glance. Haystack sits on top of GitHub and acts as the control layer for AI-generated code changes. For every pull request, it looks at the codebase, the diff, the agent trace, the author’s intent, and any verification evidence like tests, logs, commands, or screenshots. Then Haystack decides what should happen next: whether the change can move forward, needs fixes, or should be reviewed by a human. Teams use Haystack to keep code moving without turning review into rubber-stamping. It helps them merge more code, focus human attention on the changes that actually need judgment, and maintain quality as AI-generated work becomes a bigger part of development. [2]
New York City [4]
2024 [5]
Y Combinator's directory lists the company location as New York City, NY, USA. [8]
Growth & traction
2 [6]
Y Combinator lists a team size of 2. [10]
Investments
Pangram Labs
An AI research lab that develops highly accurate detection systems for AI-generated content
In the news
- Polyphron Raises $20M to Predict Drug Toxicity in Human Tissue Before Clinical TrialsAn MRI in late 2023 found a mass on Matthew Osman's pancreas. It turned out to be benign, but the months of not knowing made him ask why medicine still cannot predict what happens inside the human body. Today, his company Polyphron grows living human heart tissue in an automated foundry and uses it to teach AI what a drug will do next, backed by a fresh $20M. Find out why Osman believes the real b
- The AlleyWatch Startup Daily Funding Report: 9/17/2026The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 9/17/2026 featuring funding details for Adaptive, Polyphron, and much more.
Something wrong or missing? Send an update. Fixed within 24 hours.